Payment overview · 2025
General Payments
$157,072.77
198 reported records · 19 companies
Healthcare provider profile · identity verified
Ajit Rao, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · NEW YORK, NY · NPI 1952729956
Verified facts
What the public records show
CMS Open Payments records show Ajit Rao, MD received $157,072.77 in general payments during 2025 across 198 reported records.
Abbott Laboratories accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 59 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39,565.27 | 25.2% | 20 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$37,264.81 | 23.7% | 62 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $26,726.06 | 17.0% | 26 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $14,652.80 | 9.3% | 13 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $13,513.44 | 8.6% | 23 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $12,931.77 | 8.2% | 13 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $10,846.80 | 6.9% | 17 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $707.18 | 0.5% | 6 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $215.23 | 0.1% | 1 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $181.79 | 0.1% | 6 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $112.73 | 0.1% | 3 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $110.20 | 0.1% | 1 | 2025 |
| AXOGEN | Unresolved — no canonical attribution shown | $76.16 | 0.1% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $31.99 | 0.0% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $30.29 | 0.0% | 1 | 2025 |
| Humacyte Global, Inc. | Unresolved — no canonical attribution shown | $28.25 | 0.0% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $27.12 | 0.0% | 1 | 2025 |
| ARGON MEDICAL DEVICES, INC. | Unresolved — no canonical attribution shown | $26.25 | 0.0% | 1 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $24.63 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $89,560.00 | 32 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,820.00 | 8 |
| Travel and Lodging | $13,683.21 | 22 |
| Food and Beverage | $9,009.56 | 134 |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,000.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $25,287.67 | 24 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $25,118.10 | 21 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $18,150.00 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $15,350.00 | 6 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $12,668.18 | 10 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $11,668.37 | 8 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $11,517.36 | 11 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $10,626.21 | 13 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $10,626.21 | 13 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $10,397.46 | 13 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $7,676.91 | 2 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $2,720.00 | 2 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $2,100.00 | 3 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $1,571.00 | 5 | 2025 |
Source payment records
|
|||||
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $1,360.00 | 1 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $1,171.35 | 7 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $787.23 | 7 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $650.00 | 1 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $449.34 | 4 | 2025 |
Source payment records
|
|||||
| VALIANT CAPTIVIA Normalized: valiant captivia |
Device | Medtronic, Inc. | $422.70 | 3 | 2025 |
Source payment records
|
|||||
| IN.PACT AV Normalized: in pact av |
Device | Medtronic, Inc. | $290.06 | 4 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $290.01 | 7 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $263.59 | 3 | 2025 |
Source payment records
|
|||||
| GORE VIATORR TIPS Endoprosthesis Normalized: gore viatorr tips endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $244.21 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $215.23 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $213.77 | 4 | 2025 |
Source payment records
|
|||||
| CONCERTOTM Normalized: concertotm |
Device | Medtronic, Inc. | $197.98 | 4 | 2025 |
Source payment records
|
|||||
| Labosys Normalized: labosys |
Device | Philips North America LLC | $173.80 | 2 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $151.51 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $141.40 | 2 | 2025 |
Source payment records
|
|||||
| Philips Laser System Normalized: philips laser system |
Device | Philips North America LLC | $138.01 | 1 | 2025 |
Source payment records
|
|||||
| Other Rental Normalized: other rental |
Device | Philips North America LLC | $125.30 | 1 | 2025 |
Source payment records
|
|||||
| Laser CVX300 Normalized: laser cvx300 |
Device | Philips North America LLC | $118.56 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $112.73 | 3 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $112.73 | 3 | 2025 |
Source payment records
|
|||||
| RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Normalized: relay thoracic stent graft with plus delivery system |
Device | Bolton Medical Inc | $110.20 | 1 | 2025 |
Source payment records
|
|||||
| TREO ABDOMINAL STENT-GRAFT SYSTEM Normalized: treo abdominal stent graft system |
Device | Bolton Medical Inc | $110.20 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH ALPHA Normalized: zenith alpha |
Device | Cook Medical LLC | $67.50 | 1 | 2025 |
Source payment records
|
|||||
| Crosser IQ Normalized: crosser iq |
Device | Bard Peripheral Vascular, Inc. | $62.60 | 1 | 2025 |
Source payment records
|
|||||
| ICAST COVERED STENT SYSTEM, 6MMX22MMX120CM Normalized: icast covered stent system 6mmx22mmx120cm |
Device | Cook Medical LLC | $52.51 | 1 | 2025 |
Source payment records
|
|||||
| MVP Normalized: mvp |
Device | Medtronic, Inc. | $46.68 | 2 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| SPIDERFX Normalized: spiderfx |
Device | Medtronic, Inc. | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $31.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $31.99 | 1 | 2025 |
Source payment records
|
|||||
| Dorado Normalized: dorado |
Device | Bard Peripheral Vascular, Inc. | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| Symvess Normalized: symvess |
Biological | Humacyte Global, Inc. | $28.25 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH Normalized: zenith |
Device | Cook Medical LLC | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| CLOT MANAGEMENT Normalized: clot management |
Device | ARGON MEDICAL DEVICES, INC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| TOURGUIDE STEERABLE SHEATH Normalized: tourguide steerable sheath |
Device | Medtronic, Inc. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| COOK Normalized: cook |
Device | Cook Medical LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| ZENITH SPIRAL-Z Normalized: zenith spiral z |
Device | Cook Medical LLC | $14.10 | 2 | 2025 |
Source payment records
|
|||||
| NANOCROSS ELITE Normalized: nanocross elite |
Device | Medtronic, Inc. | $10.90 | 1 | 2025 |
Source payment records
|
|||||
| EVERFLEX PROTEGE EVERFLEX Normalized: everflex protege everflex |
Device | Medtronic, Inc. | $6.81 | 1 | 2025 |
Source payment records
|
|||||
| VIATORR Endoprosthesis Normalized: viatorr endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $3.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 29 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $157,072.77 · 198 records | Abbott Laboratories | ABRE, ACTIV.A.C., AFX2 Bifurcated Endograft System, ARTEGRAFT VASCULAR GRAFT, Alto Abdominal Stent Graft System, CHOCOLATE PTA BALLOON CATHETER, CLOT MANAGEMENT, CONCERTOTM, COOK, COROFLOW, CT THROMBECTOMY SYSTEM KIT, Crosser IQ, Dorado, ENDOCROSS Device, ENDURANT IIS, ESPRIT, EVERFLEX PROTEGE EVERFLEX, FLOWTRIEVER CATHETER, S, Flexitouch Plus, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE VIABAHN Endoprosthesis with Heparin, GORE VIABAHN VBX Balloon Expandable Endo, GORE VIATORR TIPS Endoprosthesis, HAWKONE, ICAST COVERED STENT SYSTEM, 6MMX22MMX120CM, IN.PACT AV, IV Other, Indigo System, Kerecis GraftGuide, Kerecis SurgiClose, LIMFLOW SYSTEM, LUTONIX Drug Coated Balloon, Labosys, Laser CVX300, MVP, NANOCROSS ELITE, Nimbl, Other Rental, PERCLOSE PROGLIDE, PERCLOSE PROSTYLE, Penumbra System, Philips Laser System, Product in Development, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM, RotarexS 6 F x 135 cm, SPIDERFX, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Symvess, TOURGUIDE STEERABLE SHEATH, TREO ABDOMINAL STENT-GRAFT SYSTEM, TURBOHAWK, Topical Oxygen Chamber for extremities, Torus Stent Graft System, VALIANT CAPTIVIA, VIATORR Endoprosthesis, XIENCE SKYPOINT, ZENITH, ZENITH ALPHA, ZENITH SPIRAL-Z | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error